What is a Do versus MD

Bovilis® BVD-MD

Active ingredient (s) and other ingredients

Each dose (2 ml) contains:


Active ingredients:
inactivated cytopathogenic bovine virus diarrhea (BVD) virus, type 1, strain C-86:
50 Elisa units (EU), induced at least 4.6 log2 VN units *

* Mean virus-neutralizing titer determined in the potency test

Adjuvant:
aluminum3+ (as aluminum phosphate and aluminum hydroxide) 6 - 9 mg


Other ingredients:
Methyl parahydroxybenzoate (as a preservative) 3 mg

Host system: permanent calf kidney cells

Red to pink cloudy suspension.

Application areas)

For the active immunization of cows and heifers from 8 months of age against transplacental infections of the bovine fetus with the virus of bovine viral diarrhea.

Contraindications

No.

Side effects

In very rare cases, there may be slight swelling at the injection site for up to 14 days after vaccination. A slight increase in temperature can also only very rarely occur temporarily. In very rare cases, hypersensitivity reactions up to anaphylactic shock are possible. In the case of anaphylactic reactions, appropriate treatment, e.g. with antihistamines, corticosteroids or adrenaline, is recommended.


The information on the frequency of side effects is defined as follows:

- Very common (more than 1 in 10 treated animals have side effects)
- Common (more than 1 but less than 10 animals in 100 animals)
- Uncommon (more than 1 but less than 10 animals in 1000 treated)
- Rare (more than 1 but less than 10 animals in 10,000 animals)
- Very rare (less than 1 in 10,000 animals treated, including individual reports).

If you notice any side effects, especially those not listed in the package insert, in your animal (s), please inform your veterinarian or pharmacist.

Target species (s)

Cattle (cows and heifers).

Dosage for each species, type and duration of application

Intramuscular injection at a dose of 2 ml per bovine.
All cattle from 8 months of age can be vaccinated.

Fetal protection can be expected if the primary series is completed 4 weeks before the start of pregnancy. Animals vaccinated later than 4 weeks before the onset of gestation or in early pregnancy will not develop fetal protection.

Individual vaccination
Basic immunization:
Two vaccinations every 4 weeks, with the second vaccination not later than 4 weeks before the onset of pregnancy.

Revaccination:
4 weeks before the start of the next pregnancy.

Herd vaccination
Basic immunization:
Two vaccinations at an interval of 4 weeks. All cattle from 8 months of age must be vaccinated.


Revaccinations:
One vaccination 6 months after the basic vaccination course has been completed, as well as all further booster vaccinations at an interval not greater than 12 months.

For revaccination, the vaccine can be used to reconstitute Bovilis IBR Marker live in cattle from 15 months of age (i.e. animals that have previously been vaccinated separately with Bovilis BVD-MD and Bovilis IBR Marker live), and the following instructions are to be followed:

Bovilis IBR Marker live Bovilis BVD-MD

5 cans + 10 ml

10 cans + 20 ml

25 cans + 50 ml

50 cans + 100 ml

A single dose (2 ml) of Bovilis BVD-MD mixed with Bovilis IBR Marker live is administered intramuscularly.
The package insert for Bovilis IBR Marker live should be read before the mixed vaccines are administered.

Instructions for correct use

Bring the vaccine to room temperature (15 ° C - 25 ° C) and shake vigorously before use.
Use only clean, sterile vaccination equipment.

Appearance after reconstitution of Bovilis IBR Marker live in Bovilis BVD-MD:
As specified for Bovilis BVD-MD alone.

waiting period

Zero days

Special storage instructions

Keep medicines out of the reach of children.
Store in a refrigerator (2 C - 8 C). Do not freeze.
Do not use this veterinary medicinal product after the expiry date which is stated on the label.
Shelf life after first opening the container: 10 hours.
Shelf life after mixing with Bovilis IBR Marker live: 3 hours (at room temperature).

Special warnings

Special warnings for each target species:
Vaccinate only healthy animals.


Special precautions for the user:
In the event of accidental self-injection, seek medical advice immediately and show the package insert or the label.


Pregnancy:
The vaccine can be used during pregnancy.


Interactions with other drugs and other forms of interaction:
The data presented on the harmlessness and efficacy show that for the revaccination to be carried out - in cattle from 15 months of age (i.e. animals that were previously vaccinated separately with Bovilis BVD-MD and Bovilis IBR marker live) - this vaccine with Bovilis IBR Marker can be mixed and administered live (in member states where this vaccine is approved). The package insert for Bovilis IBR Marker live should be read before the mixed vaccines are administered. The observed adverse reactions after administration of a dose or an overdose of the mixed vaccines are no different from those described after administration of the vaccines separately.
No information is available on the harmlessness and efficacy of the vaccine when used at the same time as another veterinary product with the exception of the vaccine mentioned above. Whether the vaccine should be used before or after administration of another veterinary product must therefore be decided on a case-by-case basis.


Overdose (symptoms, emergency measures, antidotes):
Symptoms after a double dose are no different from those after a single dose.


Incompatibilities:
Do not mix with other veterinary medicinal products except with Bovilis IBR Marker live (for revaccination only).

Take special precautions for the disposal of unused medicinal product or waste materials, if necessary

Unused veterinary medicinal products or waste materials derived from them must be disposed of in accordance with national regulations.

was standing

May 2017

More information

Bovilis BVD-MD is an inactivated vaccine containing 50 Elisa units (EU) of inactivated cytopathogenic BVDV type 1, strain C-86, per dose, which induce at least 4.6 log2 VN units. Virus cultivation takes place in cell cultures, beta-propiolactone is used for inactivation. The antigen is adsorbed onto an aluminum salt adjuvant. The vaccine contains methyl parahydroxybenzoate as a preservative and traces of antibiotics and calf serum as residues from antigen production.

Containers made of glass (hydrolytic class I, Ph.Eur.) Or plastic (polyethylene terephthalate) closed with a rubber stopper and an aluminum cap.


Pack sizes:
Cardboard box with 1 glass bottle or 1 plastic bottle of 2 ml (1 dose)
Cardboard box with 1 glass bottle or 1 plastic bottle of 10 ml (5 doses)
Cardboard box with 1 glass bottle or 1 plastic bottle of 20 ml (10 doses)
Cardboard box with 1 glass bottle or 1 plastic bottle of 50 ml (25 doses)
Folding box with 1 glass bottle or 1 plastic bottle of 100 ml (50 doses)
Cardboard box with 1 glass bottle or 1 plastic bottle of 250 ml (125 cans)

Not all pack sizes may be marketed.


For animals.

EN: Prescription only
AT: Prescription and pharmacy only


DE: Approval no. 180a / 96
AT: Z.Nr. 8-20202

For more information about the veterinary medicinal product, please contact the local representative of the marketing authorization holder.